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Botulinum toxin has been used to treat plantar
blistering and pain in 7 epidermolysis bullosa simplex
patients, includingone child,with excellent but transient
success (Table I). Most of these patients were treated
with abobotulinumtoxinA, including the indexed
pediatric patient. We recently investigated the use of
onabotulinumtoxinA to treat epidermolysis bullosa
simplex (EBS) symptoms in a pediatric patient, making
this successful treatment unusual. Dose equivalence
ranging from 2:1 to 4:1 abobotulinumtoxinA to
onabotulinumtoxinA, respectively, has been suggested
for the treatment of glabellar wrinkles and axillary
hyperhidrosis, but further evidence is needed to deter-
mine the appropriate dose for management of EBS
symptoms in both pediatric and adult patients.3
Additionally, the relative importance of the toxin’s role
inhyperhidrosis reductionandon localneurotransmitter
release in neuropathic pathways deserves exploration.
CASE REPORT
A6-year-oldAfrican-American boywith a history of
EBS presented with painful blisters on the plantar
aspect of both feet. The hyperhidrosis was fairly well
controlled during the winter months with glycopyrro-
late, 1 mg daily. However, he noted continued
exacerbations of plantar blistering, hyperhidrosis,
tenderness, and malodor with warmer temperatures.
Given the recalcitrance toother interventions and after
informed consent, the patient was administered 50 U
of onabotulinumtoxinA in 4 mL preserved normalthe Department of Dermatology, University of Iowa Hospitals
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ail: hholahan@uci.edu.saline under general anesthesia in the operating room
in January 2013. Injections were intradermal and
placed 1.5 to 2 cm apart, 1 U per site on the weight-
bearing areas of theplantar surface: sole, ball, andheel
of each foot, excluding the arch. A second
onabotulinumtoxinA treatment of 100 U, 2 U per
site, was given 4 months after the first administration.
The patient tolerated both procedures well without
complication He experienced decreased pain, bullae,
malodor, and less hyperhidrosis, first noted approxi-
mately 2 weeks after each treatment. The patient
continued to have baseline pain along the plantar
surface of his feet, especially with increased physical
activity. However, overall pain was decreased, which
was attributed to fewer and smaller bullae. The
patient’s symptoms were noted to recur approxi-
mately 3 months after each onabotulinumtoxinA
injection. He received 2 further treatments using the
same dosing regimen and denied any additional side
effects. Of note, he is able to stay involved with sports
activities, including football, in the summer and fall
because of his improvement.
DISCUSSION
EBS results from mutations in either KRT5 or
KRT14, encoding partner keratins 5 or 14. TheJAAD Case Reports 2016;2:259-60.
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Table I. Reported cases of EBS symptoms treated with botulinum toxin
Study Age, y Location Dosing regimen*
Time to
effect
Total
treatments
Duration
of effect Course
Abitbol
and Zhou1
43 Right foot Botox (100 U
to 1 foot)
2 wk 1 Unknown Reduction in blistering and
surface area involvement
Swartling et al2 7 Feet Dysport (170-250 U) Unknown 3 4 mo Improvement in callosities/
pedal pain; blister
formation unchanged
Swartling et al2 46 One foot Dysport (300 U) Unknown 1 3 mo Improvement in callosities/
pedal pain/blister
formation
Swartling et al2 30 One foot Dysport (300 U) Unknown 1 — No response to treatment
Swartling et al2 46 Feet Dysport (576-600 U) Unknown 3 3 mo Callosities/blister formation/
pedal pain much
improved
Swartling et al2 33 One foot Dypsort (315 U) Unknown 1 3 mo Callosities/blister formation
improved; pedal pain not
improved
Swartling et al2 24 Feet Dysport (580-700 U) Unknown 4 3.5 mo Blister formation/pedal pain
improved; callosities not
improved
Current study 6 Feet Botulinum toxin
(50 U; 100 U total)
2 wk 2 3 mo Significant improvement
with fewer, smaller
blisters/decreased pedal
pain and odor
*Botox is manufactured by Allergan, Parsippany, NJ. Dysport is manufactured by Galderma, Fort Worth, TX.
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260 Holahan et alresultant increase in keratinocyte fragility leads to
bullae, compensatory hyperkeratosis, plantar pain,
and a decreased quality of life.4 Treatment is sup-
portive and consists primarily of wound care, avoid-
ance of mechanical stress, and minimizing excessive
skin warmth and sweating, which are both recog-
nized triggers.1,5,6
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